Quality & complianceOfficial

Denmark flags supply problems for Orifarm's Frivelle levonorgestrel 1.5 mg tablets

🇩🇰 DKMA · Tue 03 Nov 2026

The Danish Medicines Agency says increased demand has disrupted supply of Frivelle 1.5 mg tablets from Orifarm Generics, with the notice updated on 3 November 2026.

The Danish Medicines Agency (DKMA) has reported current supply difficulties with Frivelle 1.5 mg tablets, marketed by Orifarm Generics A/S. The notice was first published on 8 September 2026 and updated on 3 November 2026.

Frivelle contains levonorgestrel and carries the ATC code G03AD01. DKMA gives the cause of the problem as increased sales and demand, rather than a quality or safety issue.

The agency lists the expected period of disruption as from the start of September to the start of November 2026. The notice does not give a revised end date, nor does it describe stock levels or alternative products.

DKMA directs questions about the current status to Orifarm Generics. The notice appears in the agency's section for announcements on the supply of medicines.

What it means for your team

  • Supply-chain and QA teams in Denmark should confirm the current Frivelle position directly with Orifarm Generics, as DKMA refers status queries to the company.
  • The stated cause is increased demand, with no quality or safety concern mentioned in the notice.
  • The expected disruption window ends at the start of November 2026, but the notice does not confirm recovery, so teams should keep continuity plans in place until the company confirms supply.

Official source: DKMA ↗

Article written by VigiEye from the official source (DKMA). AI-assisted; check the source before acting.

More Quality & compliance All →